MONJUVI is an outpatient targeted immunotherapy for adult NTE patients with R/R DLBCL in 2L

Study Design Overview

L-MIND was an open-label, multicenter, single-arm, Phase 2 study in adult patients with R/R DLBCL who were not eligible for or refused ASCT.1,2

Efficacy was established based on best ORR (defined as the proportion of complete and partial responders), and DoR, as assessed by an Independent Review Committee using the International Working Group Response Criteria (Cheson 2007).1

Full study design

1-Year Primary Analysis

Review the 1-year primary analysis

Primary analysis

5-Year Long-term Analysis

Review the 5-year follow-up analysis.

Long-term analysis

The 5-year analysis data from L-MIND have not been submitted to or reviewed by the FDA, and potential inclusion of these data in the final FDA-approved labeling has yet to be determined.